Clinical trials to assess adjuvant therapeutics for severe malaria.

ABSTRACT: Despite potent anti-malarial treatment, mortality rates associated with severe falciparum malaria remain high. To attempt to improve outcome, several trials have assessed a variety of potential adjunctive therapeutics, however none to date has been shown to be beneficial. This may be due, at least partly, to the therapeutics chosen and clinical trial design used. Here, we highlight three themes that could facilitate the choice and evaluation of putative adjuvant interventions for severe malaria, paving the way for their assessment in randomized controlled trials. Most clinical trials of adjunctive therapeutics to date have been underpowered due to the large number of participants required to reach mortality endpoints, rendering these study designs challenging and expensive to conduct. Thes

SUBMITTER: Varo R 

PROVIDER: S-EPMC7382078 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature